Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 05, 2021

SELL
$80.74 - $97.7 $6,297 - $7,620
-78 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$85.07 - $109.69 $4,934 - $6,362
58 Added 290.0%
78 $7,000
Q2 2020

Aug 10, 2020

SELL
$74.18 - $108.93 $503,385 - $739,198
-6,786 Reduced 99.71%
20 $2,000
Q1 2020

May 12, 2020

BUY
$63.18 - $85.97 $349,069 - $474,984
5,525 Added 431.3%
6,806 $498,000
Q4 2019

Feb 06, 2020

BUY
$73.04 - $95.72 $83,192 - $109,025
1,139 Added 802.11%
1,281 $112,000
Q3 2019

Nov 06, 2019

BUY
$72.82 - $86.52 $4,660 - $5,537
64 Added 82.05%
142 $11,000
Q2 2019

Aug 08, 2019

SELL
$73.52 - $88.7 $1.98 Million - $2.39 Million
-26,989 Reduced 99.71%
78 $7,000
Q1 2019

May 08, 2019

BUY
$63.56 - $88.17 $1.72 Million - $2.38 Million
27,040 Added 100148.15%
27,067 $2.33 Million
Q4 2018

Feb 07, 2019

SELL
$58.5 - $69.94 $12,928 - $15,456
-221 Reduced 89.11%
27 $2,000
Q3 2018

Nov 08, 2018

BUY
$61.75 - $74.23 $14,820 - $17,815
240 Added 3000.0%
248 $17,000
Q2 2018

Aug 07, 2018

SELL
$60.85 - $83.98 $60 - $83
-1 Reduced 11.11%
8 $1,000
Q1 2018

May 18, 2018

BUY
$83.06 - $100.98 $747 - $908
9 New
9 $1,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.5B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Rational Advisors LLC Portfolio

Follow Rational Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rational Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rational Advisors LLC with notifications on news.